The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 11032 results:
[ Author(Desc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Polyzos, S. A., & Anastasilakis A. D. (2010).  A systematic review of cases reporting needle tract seeding following thyroid fine needle biopsy.. World J Surg. 34(4), 844-51.
Polyzos, S. A., Hill M. A., Fuleihan G. El- Hajj, Gnudi L., Kim Y-B., Larsson S. C., et al. (2022).  Metabolism, Clinical and Experimental: seventy years young and growing.. Metabolism. 155333.
Polyzos, S. A., & Goulis D. G. (2024).  Menopause and metabolic dysfunction-associated steatotic liver disease.. Maturitas. 108024.
Polyzos, S. A., Zeglinas C., Artemaki F., Doulberis M., Kazakos E., Katsinelos P., et al. (2018).   infection and esophageal adenocarcinoma: a review and a personal view.. Ann Gastroenterol. 31(1), 8-13.
Polyzos, S. A., Anastasilakis A. D., & Terpos E. (2013).  Serum sclerostin levels following treatment with parathyroid hormone.. J Endocrinol Invest. 36(4), 280.
Polyzos, S. A., Kita M., Efstathiadou Z., Poulakos P., Slavakis A., Sofianou D., et al. (2008).  Serum thyrotropin concentration as a biochemical predictor of thyroid malignancy in patients presenting with thyroid nodules.. J Cancer Res Clin Oncol. 134(9), 953-60.
Polyzos, S. A., Anastasilakis A. D., Bratengeier C., Woloszczuk W., Papatheodorou A., & Terpos E. (2012).  Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.. Osteoporos Int. 23(3), 1171-6.
Polyzos, S. A., Papaefthymiou A., Doulberis M., & Kountouras J. (2023).  Nonalcoholic fatty liver disease test: an external validation cohort.. Hormones (Athens).
Polyzos, S. A., & Mantzoros C. S. (2020).  Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD).. Metabolism. 154318.
Polyzos, S. A., Anastasilakis A. D., Efstathiadou Z., Litsas I., Kita M., Panagiotou A., et al. (2010).  Serum homocysteine, folate and vitamin B12 in patients with Paget's disease of bone: the effect of zoledronic acid.. J Bone Miner Metab. 28(3), 314-9.
Polyzos, S. A., Papaefthymiou A., Doulberis M., Mavridoglou G., & Kountouras J. (2021).  Helicobacter pylori infection and diabetes mellitus.. Diabetes Metab Syndr. 15(3), 845-846.
Polyzos, S. A., & Anastasilakis A. D. (2011).  Rare potential complications of thyroid fine needle biopsy.. Hippokratia. 15(2), 116-9.
Polyzos, S. A. (2017).  Endocrine and metabolic disorders interplaying with non-alcoholic fatty liver disease.. Minerva Endocrinol. 42(2), 89-91.
Polyzos, S. A., & Mantzoros C. S. (2018).  Sixty-six years of Metabolism, Clinical and Experimental: The journey of a journal and opportunities and challenges looking ahead.. Metabolism. 78, A4-A9.
Polyzos, S. A., & Goulas A. (2020).  Treatment of nonalcoholic fatty liver disease with an anti-osteoporotic medication: A hypothesis on drug repurposing.. Med Hypotheses. 110379.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Litsas I., Kita M., Arsos G., et al. (2011).  Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget's disease of bone.. Osteoporos Int. 22(1), 363-7.
Polyzos, S. A., Anastasilakis A. D., & Terpos E. (2009).  Paget's disease of bone: emphasis on treatment with zoledronic acid.. Expert Rev Endocrinol Metab. 4(5), 423-434.
Polyzos, S. A., Kountouras J., Mantzoros C. S., Polymerou V., & Katsinelos P. (2017).  Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial.. Diabetes Obes Metab. 19(12), 1805-1809.
Polyzos, S. A., & Kountouras J. (2015).  Novel Advances in the Association Between Helicobacter pylori Infection, Metabolic Syndrome, and Related Morbidity.. Helicobacter. 20(6), 405-9.
Polyzos, S. A., Kountouras J., & Mantzoros C. S. (2016).  Adipokines in nonalcoholic fatty liver disease.. Metabolism. 65(8), 1062-79.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., & Terpos E. (2023).  Wnt/beta-catenin signaling inhibitors and nonalcoholic fatty liver disease: Potential therapeutic implications.. Hepatobiliary Pancreat Dis Int.
Polyzos, S. A., & Kountouras J. (2012).  Visual vignette. Anaplastic thyroid carcinoma.. Endocr Pract. 18(1), 108.
Polyzos, S. A., Goulas A., & Papaioannidou P. (2023).  Tirzepatide for Diabetes and Obesity: A New Window to the Treatment of Non-alcoholic Steatohepatitis.. Curr Med Chem.
Polyzos, S. A., Kountouras J., Goulas A., & Duntas L. (2020).  Selenium and selenoprotein P in nonalcoholic fatty liver disease.. Hormones (Athens). 19(1), 61-72.
Polyzos, S. A., & Kountouras J. (2016).  Homocysteine in nonalcoholic steatohepatitis: A reply.. Eur J Intern Med. 35, e40-e41.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.